{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T18:12:59Z","timestamp":1794507179539,"version":"4.9.1"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.critrevonc.2024.104423","type":"journal-article","created":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T16:08:29Z","timestamp":1718640509000},"page":"104423","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Safety of intravitreal chemotherapy in the management of retinoblastoma: A systematic review of the literature"],"prefix":"10.1016","volume":"200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3973-7838","authenticated-orcid":false,"given":"Georgios","family":"Lavasidis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Strongylis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Argyrios","family":"Tzamalis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Tsinopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia E.","family":"Ntzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.critrevonc.2024.104423_bib1","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/APO.0000000000000322","article-title":"Chemotherapy for retinoblastoma: impact of intravitreal chemotherapy","volume":"10","author":"Raval","year":"2020","journal-title":"Asia Pac. J. Ophthalmol. (Philos.)"},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104423_bib2","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.4103\/ijo.IJO_721_20","article-title":"Modern treatment of retinoblastoma: A 2020 review","volume":"68","author":"Ancona-Lezama","year":"2020","journal-title":"Indian J. Ophthalmol."},{"key":"10.1016\/j.critrevonc.2024.104423_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.822330","article-title":"Treatment of Retinoblastoma: What Is the Latest and What Is the Future","volume":"12","author":"Schaiquevich","year":"2022","journal-title":"Front Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104423_bib4","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1001\/archopht.1996.01100140521001","article-title":"Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy","volume":"114","author":"Gallie","year":"1996","journal-title":"Arch. Ophthalmol."},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104423_bib5","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1001\/archopht.1996.01100140548005","article-title":"Chemotherapy plus local treatment in the management of intraocular retinoblastoma","volume":"114","author":"Murphree","year":"1996","journal-title":"Arch. Ophthalmol."},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104423_bib6","first-page":"1548","article-title":"Long-term (20-year) real-world outcomes of intravenous chemotherapy (chemoreduction) for retinoblastoma in 964 eyes of 554 patients at a single centre","volume":"104","author":"Shields","year":"2020","journal-title":"Br. J. Ophthalmol."},{"issue":"101","key":"10.1016\/j.critrevonc.2024.104423_bib7","first-page":"11","article-title":"Classification and staging of retinoblastoma","volume":"31","author":"Fabian","year":"2018","journal-title":"Community Eye Health"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104423_bib8","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/eye.2015.179","article-title":"Conservative treatment of retinoblastoma: a prospective phase II randomized trial of neoadjuvant chemotherapy followed by local treatments and chemothermotherapy","volume":"30","author":"Lumbroso-Le Rouic","year":"2016","journal-title":"Eye (Lond.)"},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104423_bib9","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/jjco\/hyg113","article-title":"Eye-preservation treatment of retinoblastoma with vitreous seeding","volume":"33","author":"Kaneko","year":"2003","journal-title":"Jpn J. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.critrevonc.2024.104423_bib10","doi-asserted-by":"crossref","first-page":"7569","DOI":"10.1158\/1078-0432.CCR-05-0849","article-title":"Topotecan combination chemotherapy in two new rodent models of retinoblastoma","volume":"11","author":"Laurie","year":"2005","journal-title":"Clin. Cancer Res"},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104423_bib11","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1167\/tvst.10.11.10","article-title":"Efficacy, Toxicity, and Pharmacokinetics of Intra-Arterial Chemotherapy Versus Intravenous Chemotherapy for Retinoblastoma in Animal Models and Patients","volume":"10","author":"Daniels","year":"2021","journal-title":"Transl. Vis. Sci. Technol."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104423_bib12","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/ICU.0000000000000091","article-title":"Targeted retinoblastoma management: when to use intravenous, intra-arterial, periocular, and intravitreal chemotherapy","volume":"25","author":"Shields","year":"2014","journal-title":"Curr. Opin. Ophthalmol."},{"key":"10.1016\/j.critrevonc.2024.104423_bib13","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.11941.1","article-title":"Recent advancements in the management of retinoblastoma and uveal melanoma","volume":"7","author":"Schefler","year":"2018","journal-title":"F1000Res"},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104423_bib14","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/archophthalmol.2012.1983","article-title":"Intravitreal melphalan for refractory or recurrent vitreous seeding from retinoblastoma","volume":"130","author":"Ghassemi","year":"2012","journal-title":"Arch. Ophthalmol."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104423_bib15","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1097\/IAE.0000000000000903","article-title":"INTRAVITREOUS CHEMOTHERAPY FOR ACTIVE VITREOUS SEEDING FROM RETINOBLASTOMA: Outcomes After 192 Consecutive Injections. The 2015 Howard Naquin Lecture","volume":"36","author":"Shields","year":"2016","journal-title":"Retina"},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104423_bib16","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3928\/01913913-20160719-04","article-title":"Retinoblastoma Control With Primary Intra-arterial Chemotherapy: Outcomes Before and During the Intravitreal Chemotherapy Era","volume":"53","author":"Shields","year":"2016","journal-title":"J. Pedia Ophthalmol. Strabismus"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104423_bib17","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1177\/11206721221093018","article-title":"Targeted chemotherapy in retinoblastoma: A step forward from patient survival to globe survival","volume":"33","author":"Naseripour","year":"2023","journal-title":"Eur. J. Ophthalmol."},{"key":"10.1016\/j.critrevonc.2024.104423_bib18","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1755-3768.1961.tb00269.x","article-title":"Present therapeutic resources in retinoblastoma","volume":"39","author":"Ericson","year":"1961","journal-title":"Acta Ophthalmol. (Copenh)"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104423_bib19","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1136\/bjo.79.2.194","article-title":"Intravitreal chemotherapy for recurrent retinoblastoma in an only eye","volume":"79","author":"Seregard","year":"1995","journal-title":"Br. J. Ophthalmol."},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104423_bib20","article-title":"Outcomes of Group D retinoblastoma with resistant vitreous seeds after integration of intravitreal chemotherapy to the treatment protocol","volume":"12","author":"Amin","year":"2020","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104423_bib21","doi-asserted-by":"crossref","first-page":"141","DOI":"10.4103\/0301-4738.154390","article-title":"The role of intravitreal chemotherapy for retinoblastoma","volume":"63","author":"Manjandavida","year":"2015","journal-title":"Indian J. Ophthalmol."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104423_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2011.02.005","article-title":"Intravitreal methotrexate for retinoblastoma","volume":"118","author":"Kivel\u00e4","year":"2011","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104423_bib23","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00417-022-05903-3","article-title":"Addition of intravitreal carboplatin with melphalan for management of vitreous seeding in retinoblastoma","volume":"261","author":"Riazi-Esfahani","year":"2023","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104423_bib24","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1159\/000491580","article-title":"Primary intra-arterial chemotherapy for retinoblastoma in the intravitreal chemotherapy era: five years of experience","volume":"5","author":"Dalvin","year":"2019","journal-title":"Ocul. Oncol. Pathol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104423_bib25","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1186\/s12885-020-07314-1","article-title":"Effectiveness of intravitreal chemotherapy-assisted endoresection in monocular patients with group D retinoblastoma","volume":"20","author":"Yu","year":"2020","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104423_bib26","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/13816810.2018.1443343","article-title":"Intravitreal chemotherapy and laser for newly visible subretinal seeds in retinoblastoma","volume":"39","author":"Abramson","year":"2018","journal-title":"Ophthalmic Genet"},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104423_bib27","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s10792-015-0129-8","article-title":"Alternated intra-arterial and intravitreal chemotherapy for advanced intraocular retinoblastoma: preliminary successful results without systemic chemotherapy","volume":"35","author":"De Francesco","year":"2015","journal-title":"Int Ophthalmol."},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104423_bib28","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1136\/bjophthalmol-2013-303188","article-title":"Evaluating the risk of extraocular tumour spread following intravitreal injection therapy for retinoblastoma: a systematic review","volume":"97","author":"Smith","year":"2013","journal-title":"Br. J. Ophthalmol."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104423_bib29","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1136\/bjophthalmol-2013-303885","article-title":"Ocular side effects following intravitreal injection therapy for retinoblastoma: a systematic review","volume":"98","author":"Smith","year":"2014","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.critrevonc.2024.104423_bib30","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2024.104423_bib31","series-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [Internet]","author":"Wells","year":"2011"},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104423_bib32","first-page":"788","article-title":"Evidence-based medicine: How to practice & teach EBM","volume":"157","author":"Haynes","year":"1997","journal-title":"Can. Med. Assoc. J."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104423_bib33","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.oret.2022.11.003","article-title":"Intravitreal Carboplatin as Salvage Treatment for Progressive Vitreous Disease in Retinoblastoma: A Phase I Clinical Trial","volume":"7","author":"King","year":"2023","journal-title":"Ophthalmol. Retin."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104423_bib34","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jaapos.2019.03.002","article-title":"Heterochromia following intravitreal chemotherapy in two cases","volume":"23","author":"Camp","year":"2019","journal-title":"J. AAPOS"},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104423_bib35","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1177\/11206721211023317","article-title":"Management of cataracts secondary to intravitreal chemotherapy injections for retinoblastoma seeding","volume":"32","author":"Ko\u00e7","year":"2022","journal-title":"Eur. J. Ophthalmol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104423_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0084247","article-title":"Electroretinogram monitoring of dose-dependent toxicity after ophthalmic artery chemosurgery in retinoblastoma eyes: six year review","volume":"9","author":"Francis","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104423_bib37","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/bjophthalmol-2018-312037","article-title":"Intravitreal chemotherapy in retinoblastoma: expanded use beyond intravitreal seeds","volume":"103","author":"Abramson","year":"2019","journal-title":"Br. J. Ophthalmol."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104423_bib38","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3109\/13816810.2014.973045","article-title":"Classification and management of seeds in retinoblastoma. Ellsworth Lecture Ghent August 24th 2013","volume":"35","author":"Munier","year":"2014","journal-title":"Ophthalmic Genet"},{"key":"10.1016\/j.critrevonc.2024.104423_bib39","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.2147\/OPTH.S417370","article-title":"Ocular Survival Following Intravitreal Melphalan as Adjuvant Treatment for Vitreous Retinoblastoma Seeding","volume":"17","author":"Alahmadi","year":"2023","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.critrevonc.2024.104423_bib40","doi-asserted-by":"crossref","DOI":"10.17219\/acem\/166180","article-title":"Efficacy of intravitreal injections of melphalan in the treatment of retinoblastoma vitreous seeding","author":"Cie\u015blik","year":"2023","journal-title":"Adv. Clin. Exp. Med"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104423_bib41","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1159\/000520952","article-title":"Combination of brachytherapy and intravitreal chemotherapy in the treatment of retinoblastoma with vitreous seeding","volume":"8","author":"Schl\u00fcter","year":"2022","journal-title":"Ocul. Oncol. Pathol."},{"key":"10.1016\/j.critrevonc.2024.104423_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.696787","article-title":"Safety and Efficacy of Intravitreal Chemotherapy (Melphalan) to Treat Vitreous Seeds in Retinoblastoma","volume":"12","author":"Yousef","year":"2021","journal-title":"Front Pharm."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104423_bib43","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000511980","article-title":"Eye Salvage with Intra-Arterial and Intra-Vitreal Chemotherapy in Patients with Retinoblastoma: 8-Year Single-Institution Experience in Colombia","volume":"7","author":"Gonz\u00e1lez","year":"2021","journal-title":"Ocul. Oncol. Pathol."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104423_bib44","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/bjophthalmol-2020-318529","article-title":"Evaluation of intravitreal topotecan dose levels, toxicity and efficacy for retinoblastoma vitreous seeds: a preclinical and clinical study","volume":"106","author":"Bogan","year":"2022","journal-title":"Br. J. Ophthalmol."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104423_bib45","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1159\/000509080","article-title":"Intravitreal Melphalan for Retinoblastoma: The Impact of Toxicity on Recurrence and Ultimate Globe Salvage","volume":"6","author":"Berry","year":"2020","journal-title":"Ocul. Oncol. Pathol."},{"key":"10.1016\/j.critrevonc.2024.104423_bib46","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2147\/OPTH.S282741","article-title":"Management and Outcomes of Unilateral Group D Tumors in Retinoblastoma","volume":"15","author":"Amin","year":"2021","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.critrevonc.2024.104423_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2021.108439","article-title":"Intravitreal melphalan hydrochloride vs propylene glycol-free melphalan for retinoblastoma vitreous seeds: Efficacy, toxicity and stability in rabbits models and patients","volume":"204","author":"Bogan","year":"2021","journal-title":"Exp. Eye Res"},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104423_bib48","article-title":"Retinoblastoma management in 13q deletion syndrome patients using super-selective chemotherapies and other cancer-directed interventions","volume":"68","author":"Cobbs","year":"2021","journal-title":"Pedia Blood Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104423_bib49","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1177\/1120672120957587","article-title":"Secondary intra-arterial chemotherapy and\/or intravitreal chemotherapy as salvage treatment for retinoblastoma","volume":"31","author":"Mirzayev","year":"2021","journal-title":"Eur. J. Ophthalmol."},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104423_bib50","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1136\/bjophthalmol-2020-316588","article-title":"Is intravitreal topotecan toxic to retinal function?","volume":"105","author":"Nadelmann","year":"2021","journal-title":"Br. J. Ophthalmol."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104423_bib51","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1159\/000491432","article-title":"Precision intravitreal chemotherapy for localized vitreous seeding of retinoblastoma","volume":"5","author":"Yu","year":"2019","journal-title":"Ocul. Oncol. Pathol."},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104423_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0235016","article-title":"Comparison of efficacy and toxicity of intravitreal melphalan formulations for retinoblastoma","volume":"15","author":"Hsieh","year":"2020","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104423_bib53","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s10384-020-00743-2","article-title":"Comparison of intravitreal melphalan with and without topotecan in the management of vitreous disease in retinoblastoma","volume":"64","author":"Kiratli","year":"2020","journal-title":"Jpn J. Ophthalmol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104423_bib54","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/IAE.0000000000002782","article-title":"Toxicity and efficacy of intravitreal melphalan for retinoblastoma: 25 \u00b5g versus 30 \u00b5g","volume":"41","author":"Liao","year":"2021","journal-title":"Retina"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104423_bib55","doi-asserted-by":"crossref","first-page":"257","DOI":"10.18240\/ijo.2020.02.09","article-title":"Combined intra-arterial chemotherapy and intravitreal melphalan for the treatment of advanced unilateral retinoblastoma","volume":"13","author":"Liang","year":"2020","journal-title":"Int J. Ophthalmol."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104423_bib56","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1177\/1078155220904410","article-title":"Intravitreal melphalan therapy for vitreous seeds in retinoblastoma: Implementation and outcomes of a new chemotherapy protocol","volume":"26","author":"Solana-Altabella","year":"2020","journal-title":"J. Oncol. Pharm. Pr."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104423_bib57","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1080\/13816810.2019.1711427","article-title":"Retinopathy in young retinoblastoma patients receiving a chemotherapy treatment: clinical trials and morphometric analysis","volume":"40","author":"Saakyan","year":"2019","journal-title":"Ophthalmic Genet"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104423_bib58","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000493687","article-title":"Posterior Vitreous Detachment and the Associated Risk of Retinal Toxicity with Intravitreal Melphalan Treatment for Retinoblastoma","volume":"5","author":"Berry","year":"2019","journal-title":"Ocul. Oncol. Pathol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104423_bib59","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12886-019-1059-4","article-title":"Ocular toxicity of intravitreal melphalan for retinoblastoma in Chinese patients","volume":"19","author":"Xue","year":"2019","journal-title":"BMC Ophthalmol."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104423_bib60","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1159\/000486098","article-title":"Integrated Treatment during the Intravitreal Melphalan Era: Concurrent Intravitreal Melphalan and Systemic Chemoreduction","volume":"4","author":"Berry","year":"2018","journal-title":"Ocul. Oncol. Pathol."},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104423_bib61","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1001\/jamaophthalmol.2017.4600","article-title":"Risk of Extraocular Extension in Eyes With Retinoblastoma Receiving Intravitreous Chemotherapy","volume":"135","author":"Francis","year":"2017","journal-title":"JAMA Ophthalmol."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104423_bib62","first-page":"445","article-title":"Safety and efficacy of posterior sub-Tenon\u2019s carboplatin injection versus intravitreal melphalan therapy in the management of retinoblastoma with secondary vitreous seeds","volume":"11","author":"Said","year":"2018","journal-title":"Int J. Ophthalmol."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104423_bib63","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1136\/bjophthalmol-2017-310641","article-title":"Intravitreal topotecan in the management of refractory and recurrent vitreous seeds in retinoblastoma","volume":"102","author":"Rao","year":"2018","journal-title":"Br. J. Ophthalmol."},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104423_bib64","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/j.ophtha.2017.05.034","article-title":"Not All Seeds Are Created Equal: Seed Classification Is Predictive of Outcomes in Retinoblastoma","volume":"124","author":"Berry","year":"2017","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104423_bib65","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.ophtha.2017.04.010","article-title":"Retinoblastoma Vitreous Seed Clouds (Class 3): A Comparison of Treatment with Ophthalmic Artery Chemosurgery with or without Intravitreous and Periocular Chemotherapy","volume":"124","author":"Francis","year":"2017","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104423_bib66","doi-asserted-by":"crossref","first-page":"423","DOI":"10.5301\/ejo.5000921","article-title":"Intravitreal chemotherapy in the management of vitreous disease in retinoblastoma","volume":"27","author":"Kiratli","year":"2017","journal-title":"Eur. J. Ophthalmol."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104423_bib67","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.ophtha.2016.12.015","article-title":"Efficacy and Toxicity of Intravitreous Chemotherapy for Retinoblastoma: Four-Year Experience","volume":"124","author":"Francis","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.critrevonc.2024.104423_bib68","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/4387286","article-title":"Intravitreal melphalan for vitreous seeds: initial experience in China","volume":"2016","author":"Ji","year":"2016","journal-title":"J. Ophthalmol."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104423_bib69","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00417-015-3202-0","article-title":"Combined intravitreal melphalan and intravenous\/intra-arterial chemotherapy for retinoblastoma with vitreous seeds","volume":"254","author":"Lee","year":"2016","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104423_bib70","doi-asserted-by":"crossref","first-page":"942","DOI":"10.3928\/23258160-20151008-07","article-title":"Intravitreal Lower-Dose (20 \u00b5g) Melphalan for Persistent or Recurrent Retinoblastoma Vitreous Seeds","volume":"46","author":"Tuncer","year":"2015","journal-title":"Ophthalmic Surg. Lasers Imaging Retin."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104423_bib71","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s10384-015-0378-0","article-title":"Intravitreal injection of melphalan for intraocular retinoblastoma","volume":"59","author":"Suzuki","year":"2015","journal-title":"Jpn J. Ophthalmol."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104423_bib72","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1001\/jamaophthalmol.2014.414","article-title":"Combined intravitreal melphalan and topotecan for refractory or recurrent vitreous seeding from retinoblastoma","volume":"132","author":"Ghassemi","year":"2014","journal-title":"JAMA Ophthalmol."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104423_bib73","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1136\/bjophthalmol-2011-301450","article-title":"Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications","volume":"96","author":"Munier","year":"2012","journal-title":"Br. J. Ophthalmol."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104423_bib74","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1136\/bjophthalmol-2011-301016","article-title":"Profiling safety of intravitreal injections for retinoblastoma using an anti-reflux procedure and sterilisation of the needle track","volume":"96","author":"Munier","year":"2012","journal-title":"Br. J. Ophthalmol."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104423_bib75","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3928\/01913913-20161116-01","article-title":"Intraocular Pressure Changes Following Intravitreal Melphalan and Topotecan for the Treatment of Retinoblastoma With Vitreous Seeding","volume":"54","author":"Karl","year":"2017","journal-title":"J. Pedia Ophthalmol. Strabismus"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104423_bib76","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jcjo.2020.01.015","article-title":"Endophthalmitis following intravitreal injection of anti-vascular endothelial growth factor agents","volume":"55","author":"Storey","year":"2020","journal-title":"Can. J. Ophthalmol."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104423_bib77","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3341\/kjo.2017.0036","article-title":"Endophthalmitis","volume":"31","author":"Sheu","year":"2017","journal-title":"Korean J. Ophthalmol."},{"key":"10.1016\/j.critrevonc.2024.104423_bib78","first-page":"14","article-title":"Vitreous injection therapy of melphalan for retinoblastoma","author":"Suzuki","year":"2011","journal-title":": XVth Biannu. Meet., Int. Soc. Ocul. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104423_bib79","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s10633-012-9358-6","article-title":"Persistence of retinal function after intravitreal melphalan injection for retinoblastoma","volume":"126","author":"Brodie","year":"2013","journal-title":"Doc. Ophthalmol."},{"issue":"13","key":"10.1016\/j.critrevonc.2024.104423_bib80","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1001\/jama.1983.03330370053031","article-title":"If nothing goes wrong, is everything all right? Interpreting zero numerators","volume":"249","author":"Hanley","year":"1983","journal-title":"JAMA"},{"key":"10.1016\/j.critrevonc.2024.104423_bib81","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ajo.2021.09.026","article-title":"Contemporary Update of Retinoblastoma in China: Three-Decade Changes in Epidemiology, Clinical Features, Treatments, and Outcomes","volume":"236","author":"Luo","year":"2022","journal-title":"Am. J. Ophthalmol."},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104423_bib82","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.ophtha.2020.05.051","article-title":"A Multicenter, International Collaborative Study for American Joint Committee on Cancer Staging of Retinoblastoma: Part II: Treatment Success and Globe Salvage","volume":"127","author":"Tomar","year":"2020","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104423_bib83","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.ophtha.2015.01.017","article-title":"The classification of vitreous seeds in retinoblastoma and response to intravitreal melphalan","volume":"122","author":"Francis","year":"2015","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104423_bib84","article-title":"Clinical and ultrastructural changes in the rabbit retina at various doses and numbers of intravitreal melphalan injections","author":"Bobrova","year":"2022","journal-title":"J. Ophthalmol. (Ukr. )\/Oftal\u2032mologi\u010deskij \u017durnal"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104423_bib85","first-page":"120","article-title":"Optical and structural development of the crystalline lens in childhood","volume":"39","author":"Mutti","year":"1998","journal-title":"Invest Ophthalmol. Vis. Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104423_bib86","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4103\/NJCA.NJCA_16_20","article-title":"Anatomical and clinical characteristics of paediatric and adult eyes","volume":"10","author":"Sunita","year":"2021","journal-title":"Natl. J. Clin. Anat."},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104423_bib87","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1001\/jamaophthalmol.2015.3119","article-title":"Anterior ocular toxicity of intravitreous melphalan for retinoblastoma","volume":"133","author":"Francis","year":"2015","journal-title":"JAMA Ophthalmol."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104423_bib88","doi-asserted-by":"crossref","first-page":"369","DOI":"10.4103\/ijo.IJO_125_21","article-title":"Cataract in retinopathy of prematurity \u2013 A review","volume":"70","author":"Khokhar","year":"2022","journal-title":"Indian J. Ophthalmol."},{"key":"10.1016\/j.critrevonc.2024.104423_bib89","series-title":"Research Triangle Park","author":"Alkeran [package insert]","year":"2007"},{"key":"10.1016\/j.critrevonc.2024.104423_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2019.05.005","article-title":"Conservative management of retinoblastoma: Challenging orthodoxy without compromising the state of metastatic grace. \u201cAlive, with good vision and no comorbidity","volume":"73","author":"Munier","year":"2019","journal-title":"Prog. Retin Eye Res"},{"key":"10.1016\/j.critrevonc.2024.104423_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121493","article-title":"Topical instillation of cell-penetrating peptide-conjugated melphalan blocks metastases of retinoblastoma","volume":"284","author":"Jiang","year":"2022","journal-title":"Biomaterials"},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104423_bib92","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000524919","article-title":"Emerging New Therapeutics for Retinoblastoma","volume":"8","author":"Raval","year":"2022","journal-title":"Ocul. Oncol. Pathol."},{"issue":"476","key":"10.1016\/j.critrevonc.2024.104423_bib93","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat9321","article-title":"Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01","volume":"11","author":"Pascual-Pasto","year":"2019","journal-title":"Sci. Transl. Med"},{"key":"10.1016\/j.critrevonc.2024.104423_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103414","article-title":"Therapeutic interventions for childhood cancer: An umbrella review of randomized evidence","volume":"164","author":"Lavasidis","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104423_bib95","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1186\/s13063-018-2925-8","article-title":"Clinical significance in pediatric oncology randomized controlled treatment trials: a systematic review","volume":"19","author":"Howard","year":"2018","journal-title":"Trials"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104423_bib96","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-1171","article-title":"Researchers\u2019, regulators\u2019, and sponsors\u2019 views on pediatric clinical trials: a multinational study","volume":"138","author":"Joseph","year":"2016","journal-title":"Pediatrics"},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104423_bib97","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/jcph.1359","article-title":"Accelerating Drug Development in Pediatric Oncology With the Clinical Pharmacology Storehouse","volume":"59","author":"Shebley","year":"2019","journal-title":"J. Clin. Pharm."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824001665?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824001665?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T02:15:07Z","timestamp":1720923307000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842824001665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":97,"alternative-id":["S1040842824001665"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104423","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of intravitreal chemotherapy in the management of retinoblastoma: A systematic review of the literature","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104423","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104423"}}